Articles From: Tax inversions help, not hurt, the economy to NASDAQ OMX Lists AdvisorShares Sunrise Global Multi-Strategy ETF (Symbol: MULT)


2014/8/8
By Diana Furchtgott-Roth, MarketWatch Opinion: They enable companies to use more of their profits for reinvestment -Diana Furchtgott-Roth; 415-439-6400; AskNewswires@dowjones.com Opinion: They enable companies to use more of their profits for reinvestment -Diana Furchtgott-Roth; 415-439-6400; AskNewswires@dowjones.com We've all heard the statistics.
Sign-up for Tax inversions help, not hurt, the economy investment picks
2014/9/4
By Diana Furchtgott-Roth, MarketWatch Americans today will see photos of fast-food worker demonstrations on national news and think the employees themselves are going on strike.
Sign-up for UPDATE: Fast-food worker strikes aren't what they appear to be investment picks
2014/9/4
By Diana Furchtgott-Roth, MarketWatch Americans today will see photos of fast-food worker demonstrations on national news and think the employees themselves are going on strike.
Sign-up for Fast-food worker strikes aren't what they appear to be investment picks
2014/9/29
Agnico Eagle's Amaruq project (formerly "IVR") near Meadowbank yields intersections up to 6.1 g/t Au over 56 metres at depth Canada NewsWire Stock Symbol: AEM (NYSE and TSX) TORONTO , Sept.
Sign-up for Agnico Eagle's Amaruq project (formerly "IVR") near Meadowbank yields intersections up to 6.1 g/t Au over 56 metres at depth investment picks
2014/9/29
Stock Symbol: AEM (NYSE and TSX) TORONTO , Sept.
Sign-up for Agnico Eagle's Amaruq project (formerly "IVR") near Meadowbank yields intersections up to 6.1 g/t Au over 56 metres at depth investment picks
2014/8/12
CHICAGO , Aug.
Sign-up for Tribune Media Company Reports Second Quarter 2014 Results investment picks
2014/7/29
- Global THV Sales Grew 21% - Full Year 2014 Sales Growth Now Projected at the High End of 1-10% Range - 2014 EPS Guidance Raised to $3.24 - $3.34 from $3.10 - Litigation Settlement Included in Reported Results IRVINE, Calif.
Sign-up for Edwards Lifesciences Reports Strong Second Quarter Results investment picks
Restructuring Plan Substantially Complete, $50 Million Annual Cost Savings Expected; Anticipate Sequential Revenue Growth in Fiscal Fourth Quarter IRVINE, Calif.
Sign-up for MFLEX Reports Fiscal 2014 Third Quarter Financial Results investment picks
- Net Sales of $292.3 Million, Up 20.5 Percent from the Third Quarter of 2013 - Non-GAAP Gross Margin of 56.0 Percent - GAAP Gross Margin of 52.5 Percent, Inclusive of Restructuring and Acquisition Related Charges - Operating Cash Flow of $54.4 Million - Book-to-Bill Ratio Greater than 1:1 ALISO VIEJO, Calif.
Sign-up for Microsemi Reports Fiscal Third Quarter 2014 Results investment picks
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Canada NewsWire LAVAL, Quebec , July 31, 2014 /CNW/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
LAVAL, Quebec , July 31, 2014 /PRNewswire/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than anticipated label Reached agreement with Irish Government and Unions to successfully restructure
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
ANGLETON, Texas , July 24, 2014 /PRNewswire/ -- Benchmark Electronics, Inc. (NYSE: BHE) , a leading integrated contract manufacturing provider, today announced financial results for its second quarter.
Sign-up for Benchmark Electronics Reports Results For The Quarter Ended June 30, 2014 investment picks
2014/9/25
By Dave Fry Last week I featured the U.S. Equity High Volatility Put Write Index Fund (HVPW). In combination with other income-oriented exchange traded funds, HVPW is a great way to diversify one's portfolio.
Sign-up for UPDATE: Income ideas: This ETF stands out as a 'bond replacement' investment picks
2014/9/26
By Dave Fry Last week I featured the U.S. Equity High Volatility Put Write Index Fund (HVPW). In combination with other income-oriented exchange traded funds, HVPW is a great way to diversify one's portfolio.
Sign-up for UPDATE: Income ideas: This ETF fills in as a 'bond replacement' investment picks
2014/10/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971702001&sourceType=1 http://media3.marketwire.com/logos/20140527-Lumenpulse_200.jpg http://www.marketwire.com/library/20141006-Lumencove-nano_LCN_01_sml.jpg Lumenpulse's Lumencove Nano, powered by the innovative Lumendrive technology, wins Next Generation Luminaires Award.
Sign-up for Lumenpulse Wins Next Generation Luminaires Award for Lumencove Nano investment picks
Egencia delivers a delightful new user experience for the iPad with personalized travel shopping, turn-by-turn trip navigation, trip alerts, and Egencia AssistMe BELLEVUE, Wash.
Sign-up for Egencia Previews the new Egencia TripNavigator App for iPad at GBTA investment picks
http://media.marketwire.com/attachments/200903/514817_FortinetNew.jpg http://media.marketwire.com/attachments/201409/TN-79919_image.jpg Yahoo! JAPAN data center network topology http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147623&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for Yahoo! JAPAN Deploys Fortinet High-Performance Firewalls for Content Delivery Network Platform investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligand’s Captisol-enabled™ Lamotrigine program.
Sign-up for Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc. investment picks
NEW YORK, June 24, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) , announced today an agreement with Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program.
Sign-up for TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4 investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that Chairman John W.
Sign-up for Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (GSK) plc has announced global revenue for Promacta™/Revolade™ for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013.
Sign-up for Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million.
Sign-up for Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc has received approval of a supplemental New Drug Application (sNDA) for the once-daily use of Promacta ® /Revolade ™ (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). 1 SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells and platelets.
Sign-up for Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the third quarter of 2014 are expected to be approximately $15 million and that non-GAAP earnings per diluted share are expected to be between $0.33 and $0.37. This compares with prior guidance issued on August 4, 2014 for total revenues to be between $13 million and $14 million and for non-GAAP earnings per diluted share to be between $0.26 and $0.29. Ligand also expects total revenues for the fourth quarter to be between $22.5 million and $24.5 million.
Sign-up for Ligand Reports Third Quarter Revenues and Expected Diluted EPS investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Merck, known as MSD outside the United States and Canada, has received approval for NOXAFIL® (posaconazole) 300 mg Concentrate for Solution for Infusion from the European Medicines Agency (EMA). Ligand earns a $550,000 milestone payment as a result of the approval.
Sign-up for Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program.
Sign-up for Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2014, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Second Quarter 2014 Financial Results investment picks
2014/8/20
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1139079&ProfileId=051205&sourceType=1 TAMPA, FL --
Sign-up for Enviro-Serv, Inc. Announces Target Acquisition Update and Second Dividend Strategy investment picks
2014/7/15
ProPay ® , a TSYS ® company , announced today a partnership with ThreatMetrix ® to provide advanced fraud prevention solutions to its customers.
Sign-up for ProPay® Launches TSYS Guardian CyberShieldSM in Partnership with ThreatMetrix® to Provide Advanced Fraud Prevention Solutions investment picks
2014/7/8
NEW YORK, July 8, 2014 (GLOBE NEWSWIRE) -- NASDAQ OMX today announced that AdvisorShares, Bethesda, MD.-based sponsor of actively managed exchange traded funds (ETFs) will launch a new ETF on Wednesday, July 9, 2014.
Sign-up for NASDAQ OMX Lists AdvisorShares Sunrise Global Multi-Strategy ETF (Symbol: MULT) investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Tax inversions help, not hurt, the economy to NASDAQ OMX Lists AdvisorShares Sunrise Global Multi-Strategy ETF (Symbol: MULT)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices